New Drug Discovery Research

R&D & Innovation

New Drug Discovery
Research

Innovating Metabolic,
Autoimmune and
Cancer Therapies

Our R&D efforts are dedicated to tackling significant unmet medical needs within our primary therapeutic areas viz Metabolic disorders, Auto-immune disorders, and Oncology. Our strategic approach has allowed us to pinpoint promising candidates and develop a strong pipeline of molecules for both preclinical and clinical development. We possess comprehensive capabilities to support drug discovery and development, from initial concept through to IND-enabling preclinical and clinical studies.

Metabolic
Disorder

Metabolic disorders can form when organs like the pancreas or liver do not work properly. This is the case with diabetes and Metabolic dysfunction-associated steatohepatitis (MASH).

Type 2 Diabetes Mellitus

Diabetes, a chronic metabolic disease marked by high blood glucose due to insufficient insulin or cell resistance in type 2 diabetes (T2DM), is the focus of our research aimed at sustained glycemic control by targeting insulin resistance and preserving β-cell function, with our new chemical entity MKP10241, currently in early phase II trials in India/abroad.

MASH/MASLD

MASH is a liver disease with fat buildup, inflammation, and cell damage, increasing the risk of chronic liver disease, type 2 diabetes, and cardiovascular issues. Two existing drugs, originally for other uses, show promise in treating MASLD/MASH when used together.

Autoimmune
Disorders

Autoimmune disorders arise when the immune system mistakenly attacks healthy tissues, affecting quality of life and often managed only by symptom-relieving treatments.

We at Mankind are aiming for novel therapeutics that could have potential therapeutic effect on umbrella of inflammatory diseases such as Rheumatoid arthritis. Ulcerative colitis, Plaque Psoriasis and Alopecia.

Oncology

We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their death. We are currently developing first in class novel therapeutics for the treatment of melanoma and lung cancer.

Immuno-oncology

Immuno-oncology, is an innovative and promising approach to cancer treatment that harnesses the body's immune system to recognize, attack, and eliminate cancer cells. We have identified novel mechanism of action to re-energize T cells so that they can retain their fitness and continue to destroy tumor cells. We are currently developing first in class novel therapeutics for the treatment of different solid tumors.

Patents &
Publications

Our commitment to innovation in drug discovery is evident in our extensive portfolio of patents and publications. Explore our key patents and scientific contributions that reflect our dedication to creating impactful, high-quality treatments for global health.

Publication

Santosh Kumar Rai, Rakesh Kumar, Amit Panwar, Mohd Imran Khan, Srinivasa Reddy B, Bhavishya Vashist, Rakesh Ishwar Patil, Sazid Ali, Anil Kumar. Pioglitazone and Ezetimibe combination improves Liver histopathology and biochemistry in experimental MASH models, Chem. Biol. Lett., 2024, 11(4), 677

Publication

Amit Panwar, Mohd. Imran Khan, Rajesh Kumar, Rakesh Kumar, Santosh Kumar Rai, Anil Kumar. Emerging novel therapeutic approaches for the treatment of Alzheimer’s disease, Advances in Alzheimer’s Disease, 2024.